Vaccinex, Inc. (VCNX) stock
VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)
Close on Oct 19, 2026Market cap $3.22MP/E –Yield –
Vaccinex gross margin
Gross margin is gross profit as a percentage of revenue.
Vaccinex's gross margin for the twelve months ending Dec 31, 2020 was 99.7%. For fiscal 2020 it was 99.7%, against 62.0% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | 99.7% | +37.7 |
| FY2019 | Dec 31, 2019 | 62.0% | +104.6 |
| FY2018 | Dec 31, 2018 | -42.7% | +35.1 |
| FY2017 | Dec 31, 2017 | -77.8% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2020 | Sep 30, 2020 | 99.7% | +154.8 |
| Q3 FY2019 | Sep 30, 2019 | 98.0% | +122.3 |
| Q2 FY2019 | Jun 30, 2019 | 36.0% | +131.2 |
| Q1 FY2019 | Mar 31, 2019 | -86.2% | −69.7 |
| Q4 FY2018 | Dec 31, 2018 | -55.2% | – |
| Q3 FY2018 | Sep 30, 2018 | -24.2% | – |
| Q2 FY2018 | Jun 30, 2018 | -95.2% | – |
| Q1 FY2018 | Mar 31, 2018 | -16.5% | – |
See a number that looks wrong?